Compare SYPR & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYPR | ELOX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 41.0M |
| IPO Year | 1996 | 2013 |
| Metric | SYPR | ELOX |
|---|---|---|
| Price | $1.81 | $15.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.8K | ★ 38.2K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,294,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $10.00 |
| 52 Week High | $4.74 | $23.40 |
| Indicator | SYPR | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 46.90 |
| Support Level | $1.79 | $10.74 |
| Resistance Level | $2.09 | $19.66 |
| Average True Range (ATR) | 0.10 | 2.72 |
| MACD | 0.02 | -0.54 |
| Stochastic Oscillator | 56.25 | 17.83 |
Sypris Solutions Inc provides products and engineering, design, and manufacturing services for a variety of critical infrastructure sectors, including energy, space, communications, defense, transport, chemical, and water. The company operates in two segments, Sypris Technologies and Sypris Electronics. Sypris Technologies segment includes the sale of forged, machined, welded and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications, whereas the Sypris Electronics segment includes revenue from circuit card and box build manufacturing, high reliability manufacturing and systems assembly and integration, for aerospace and defense, communications and space applications. The majority of revenue is derived from the Sypris Electronics segment.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.